Latest Breaking News On - Anne phelan - Page 1 : comparemela.com

BenevolentAI Announces Further Success With AstraZeneca Collaboration as Novel Heart Failure Target Selected

BenevolentAI and AstraZeneca discover novel heart failure target using AI

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive s Stephen Gunnion with positive safety data from the Phase 1a,.

BenevolentAI Announces Positive Topline Safety and Pharmacokinetic Data from the Phase Ia Clinical Study of BEN-8744 in Healthy Volunteers

Regulatory News: BenevolentAI , a leader in applying advanced AI to accelerate biopharma drug discovery, today announces positive safety data from its Phase Ia, first-in-human, clinical study of.

BenevolentAI : Inside Information / Ad Hoc Information BenevolentAI announces positive topline safety and pharmacokinetic data from the Phase Ia clinical study of BEN-8744 in healthy volunteers -March 25, 2024 at 02:05 am EDT

BenevolentAI announces positive topline safety and pharmacokinetic data from the Phase Ia clinical study of BEN-8744 in healthy volunteers London, UK, 25 March.